YCHD’s unique mechanism—modulating gut microbiota and activating the FXR-FGF15 pathway—addresses key pathological features of cholestasis, including BA dysregulation, gut barrier dysfunction, and microbial dysbiosis. Here, NR1H4 is linked to cholestasis.